Hepatology | 2021
Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH
Abstract
NASH will soon become the leading cause of liver transplantation in the United States and is also associated with increased COVID‐19 mortality. Currently, there are no Food and Drug Administration–approved drugs available that slow NASH progression or address NASH liver involvement in COVID‐19. Because animal models cannot fully recapitulate human NASH, we hypothesized that stem cells isolated directly from end‐stage liver from patients with NASH may address current knowledge gaps in human NASH pathology.